Expression of the brother of the regulator of imprinted Sites Gene in the sputum of patients with lung cancer

Korean Journal of Thoracic and Cardiovascular Surgery

Volumn 47, Issue 4, 2014, Pages 378-383

  Lee, Hae Young ^a   Kim, Jong In ^a   Cho, Sung Ho ^a   Ko, Taek Yong ^a   Kim, Hyun Su ^a   Park, Sung Dal ^a   Cho, Sung Rae ^a   Chang, Hee Kyung ^a   Hwang, Guk Jin ^a   Jung, Sang Bong ^b  

^a Kosin University College of Medicine   (South Korea)

^b Gimhae College University   (South Korea)

Author keywords

Brother of the regulator of imprinted sites; Lung neoplasms; Polymerase chain reactio; Reverse transcription

Indexed keywords

EID: 84907009512     PISSN: 2233601X     EISSN: 20936516     Source Type: Journal    
DOI: 10.5090/kjtcs.2014.47.4.378     Document Type: Article

References (17)

1. Simpson AJ, Caballero OL, Jungbluth A, Chen YT, Old LJ. Cancer/testis antigens, gametogenesis and cancer. Nat Rev Cancer 2005;5:615-25.
2. Woloszynska-Read A, James SR, Link PA, Yu J, Odunsi K, Karpf AR. DNA methylation-dependent regulation of BORIS/CTCFL expression in ovarian cancer. Cancer Immun 2007;7:21.
3. Chomez P, De Backer O, Bertrand M, De Plaen E, Boon T, Lucas S. An overview of the MAGE gene family with the identification of all human members of the family. Cancer Res 2001;61:5544-51.
4. De Plaen E, Arden K, Traversari C, et al. Structure, chromosomal localization, and expression of 12 genes of the MAGE family. Immunogenetics 1994;40:360-9.
5. Park JW, Kwon TK, Kim IH, et al. A new strategy for the diagnosis of MAGE-expressing cancers. J Immunol Methods 2002;266:79-86.
6. Melenhorst JJ, Barrett AJ. Tumor vaccines and beyond. Cytotherapy 2011;13:8-18.
7. Mellstedt H, Vansteenkiste J, Thatcher N. Vaccines for the treatment of non-small cell lung cancer: investigational approaches and clinical experience. Lung Cancer 2011;73:11-7.
8. De Necochea-Campion R, Ghochikyan A, Josephs SF, et al. Expression of the epigenetic factor BORIS (CTCFL) in the human genome. J Transl Med 2011;9:213.
9. D'Arcy V, Pore N, Docquier F, et al. BORIS, a paralogue of the transcription factor, CTCF, is aberrantly expressed in breast tumours. Br J Cancer 2008;98:571-9.
10. Risinger JI, Chandramouli GV, Maxwell GL, et al. Global expression analysis of cancer/testis genes in uterine cancers reveals a high incidence of BORIS expression. Clin Cancer Res 2007;13:1713-9.
11. Kholmanskikh O, Loriot A, Brasseur F, De Plaen E, De Smet C. Expression of BORIS in melanoma: lack of association with MAGE-A1 activation. Int J Cancer 2008;122:777-84.
12. Woloszynska-Read A, Zhang W, Yu J, et al. Coordinated cancer germline antigen promoter and global DNA hypomethylation in ovarian cancer: association with the BORIS/CTCF expression ratio and advanced stage. Clin Cancer Res 2011;17:2170-80.
13. Smith IM, Glazer CA, Mithani SK, et al. Coordinated activation of candidate proto-oncogenes and cancer testes antigens via promoter demethylation in head and neck cancer and lung cancer. PLoS One 2009;4:e4961.
14. Fiorentino FP, Macaluso M, Miranda F, et al. CTCF and BORIS regulate Rb2/p130 gene transcription: a novel mechanism and a new paradigm for understanding the biology of lung cancer. Mol Cancer Res 2011;9:225-33.
15. Bhan S, Negi SS, Shao C, et al. BORIS binding to the promoters of cancer testis antigens, MAGEA2, MAGEA3, and MAGEA4, is associated with their transcriptional activation in lung cancer. Clin Cancer Res 2011;17:4267-76.
16. Okabayashi K, Fujita T, Miyazaki J, et al. Cancer-testis antigen BORIS is a novel prognostic marker for patients with esophageal cancer. Cancer Sci 2012;103:1617-24.
17. Loukinov D, Ghochikyan A, Mkrtichyan M, et al. Antitumor efficacy of DNA vaccination to the epigenetically acting tumor promoting transcription factor BORIS and CD80 molecular adjuvant. J Cell Biochem 2006;98:1037-43